Details of the Drug Reposition

General Information of This Drug (ID: DM28AZV)

Drug Name
Relatlimab   DM28AZV

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Haematological malignancy DISCDP7W 2B33.Y Phase 2/3 [2]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)